MAPT and Cognitive impairment: As expected, fluid and imaging biomarkers of Aβ and tau pathologies increased across the AD spectrum but were not found to be different across CU-, Aβ- participants with mild cognitive impairment (MCI-) and non-AD dementia (Non-AD) groups (Supplementary Figs. S1 and S2).